September 23, 2016 09:18 AM EDT

As politicians debate the priority review voucher program, the FDA is rooting for its demise

John Carroll

Editor & Founder

Sarepta’s regulatory win on eteplirsen this week came with a big bonus. The approval delivered a rare pediatric priority review voucher that the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As politicians debate the priority review voucher program, the FDA is rooting for its demise

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

How AI can address ongoing challenges in the life sciences industry

As politi­cians de­bate the pri­or­i­ty re­view vouch­er pro­gram, the FDA is root­ing for its demise

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As politicians debate the priority review voucher program, the FDA is rooting for its demise